Brief: Biora Therapeutics Receives Pre-Ind Feedback From FDA And Provides Update On Key Programs For 2023
09/01/2023 14:03
Biora Therapeutics Inc BIOR.O :
* BIORA THERAPEUTICS RECEIVES PRE-IND FEEDBACK FROM FDA AND
PROVIDES UPDATE ON KEY PROGRAMS FOR 2023
* BIORA THERAPEUTICS INC - REMAINS ON TRACK FOR AN IND
FILING FOR
ITS PGN-600 PROGRAM FOLLOWED BY CLINICAL TRIAL INITIATION
Source text for Eikon: ID:nGNX7MWf6X
Further company coverage: BIOR.O
Recent news on Biora Therapeutics
See all newsBiora Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Biora Therapeutics Provides Corporate Update And Reports Third Quarter 2024 Financial Results
Biora Therapeutics Inc expected to post a loss of $3.85 a share - Earnings Preview
Biora Therapeutics Inc expected to post a loss of $3.85 a share - Earnings Preview
Brief: Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules